{
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "ABDX.L",
  "generated_at": "2026-01-12T05:21:42.846812Z",
  "top_card": {
    "ticker": "ABDX.L",
    "company_name": "Abingdon Health Plc",
    "sector": "Healthcare",
    "market_cap_gbp": 15692365,
    "days_active": 1120,
    "apex_score_100": 49,
    "confidence_score_100": 40,
    "ai_final_score_25": 11,
    "ai_strength": "MODERATE",
    "timing_regime": "EARLY_BUILD",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - EARLY_BUILD timing with 49/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Abingdon Health Plc",
      "sector": "Healthcare",
      "industry": "Diagnostics & Research",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 15692365,
      "current_close_price": 6.25
    },
    "basics": {
      "ticker": "ABDX.L",
      "current_price": 6.25,
      "ath": 136.2438,
      "atl": 3.6,
      "ath_date": "2021-01-26",
      "atl_date": "2022-12-16",
      "week_52_high": 9.0,
      "week_52_low": 5.1,
      "week_52_high_date": "2025-01-27",
      "week_52_low_date": "2025-08-28",
      "drawdown_from_ath_pct": 95.41,
      "data_start": "2020-12-15",
      "data_end": "2026-01-09",
      "total_bars": 1278
    },
    "latest_signal": {
      "date": "2022-12-16",
      "scan_date": "2026-01-09",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "price": 3.75,
      "drawdown_pct": 89.32,
      "ai_score": 9.0,
      "rsi": 14.3,
      "cycle_position": 0.0265,
      "holding_period_days": 1120,
      "current_pnl_pct": 66.67,
      "rally_state": "pulling_back",
      "distance_from_high_pct": -58.33,
      "Rally_Count": 1,
      "days_since_last_high": 20,
      "last_high_date": "2025-12-22",
      "lock_in_reached": true,
      "lock_in_date": "2023-06-14",
      "best_rally_pct": 300.0
    },
    "best_historical_signal": {
      "signal_date": "2022-12-16",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "entry_price": 3.75,
      "peak_price": 18.5,
      "peak_date": "2023-06-19",
      "rally_pct": 393.33,
      "days_to_peak": 185,
      "ai_score": 9.0
    },
    "all_historical_signals": [
      {
        "signal_id": "ABDX.L_2022-01-10",
        "signal_date": "2022-01-10",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 22.0,
        "current_price": 6.25,
        "current_return_pct": -71.59,
        "best_rally_pct": 7.95,
        "best_rally_date": "2022-01-17",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -73.68,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1462,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-02-09",
        "signal_date": "2022-02-09",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 15.0,
        "current_price": 6.25,
        "current_return_pct": -58.33,
        "best_rally_pct": 1.67,
        "best_rally_date": "2022-02-10",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -59.02,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1432,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-02-11",
        "signal_date": "2022-02-11",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 13.75,
        "current_price": 6.25,
        "current_return_pct": -54.55,
        "best_rally_pct": 9.09,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -58.33,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1430,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-02-14",
        "signal_date": "2022-02-14",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 12.5,
        "current_price": 6.25,
        "current_return_pct": -50.0,
        "best_rally_pct": 20.0,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -58.33,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1427,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-02-21",
        "signal_date": "2022-02-21",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 12.5,
        "current_price": 6.25,
        "current_return_pct": -50.0,
        "best_rally_pct": 20.0,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -58.33,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1420,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-03-02",
        "signal_date": "2022-03-02",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 9.5,
        "current_price": 6.25,
        "current_return_pct": -34.21,
        "best_rally_pct": 57.89,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 6,
        "distance_from_high_pct": -58.33,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1411,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-03-03",
        "signal_date": "2022-03-03",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 9.74,
        "current_price": 6.25,
        "current_return_pct": -35.83,
        "best_rally_pct": 54.0,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 8,
        "distance_from_high_pct": -58.33,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1410,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-08-04",
        "signal_date": "2022-08-04",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 9.25,
        "current_price": 6.25,
        "current_return_pct": -32.43,
        "best_rally_pct": 62.16,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -58.33,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1256,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-08-05",
        "signal_date": "2022-08-05",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 9.25,
        "current_price": 6.25,
        "current_return_pct": -32.43,
        "best_rally_pct": 62.16,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -58.33,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1255,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-08-15",
        "signal_date": "2022-08-15",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 7.11,
        "current_price": 6.25,
        "current_return_pct": -12.1,
        "best_rally_pct": 110.97,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -58.33,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1245,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-08-16",
        "signal_date": "2022-08-16",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5,
        "current_price": 6.25,
        "current_return_pct": -16.67,
        "best_rally_pct": 100.0,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -58.33,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1244,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-08-24",
        "signal_date": "2022-08-24",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.75,
        "current_price": 6.25,
        "current_return_pct": -7.41,
        "best_rally_pct": 122.22,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -58.33,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1236,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-08-25",
        "signal_date": "2022-08-25",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 6.5,
        "current_price": 6.25,
        "current_return_pct": -3.85,
        "best_rally_pct": 130.77,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -58.33,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1235,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-08-30",
        "signal_date": "2022-08-30",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.25,
        "current_price": 6.25,
        "current_return_pct": 0.0,
        "best_rally_pct": 140.0,
        "best_rally_date": "2023-06-14",
        "rally_state": "rallying",
        "Rally_Count": 6,
        "distance_from_high_pct": -58.33,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1230,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-11-24",
        "signal_date": "2022-11-24",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 5.25,
        "current_price": 6.25,
        "current_return_pct": 19.05,
        "best_rally_pct": 185.71,
        "best_rally_date": "2023-06-14",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -58.33,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1144,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-11-29",
        "signal_date": "2022-11-29",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 4.25,
        "current_price": 6.25,
        "current_return_pct": 47.06,
        "best_rally_pct": 252.94,
        "best_rally_date": "2023-06-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -58.33,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1139,
        "status": "historical"
      },
      {
        "signal_id": "ABDX.L_2022-12-16",
        "signal_date": "2022-12-16",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 3.75,
        "current_price": 6.25,
        "current_return_pct": 66.67,
        "best_rally_pct": 300.0,
        "best_rally_date": "2023-06-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -58.33,
        "days_since_last_high": 20,
        "lock_in_reached": true,
        "age_days": 1122,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 17,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 140.87,
      "median_rally_pct": 100.0,
      "best_rally_pct": 393.33,
      "worst_rally_pct": 13.64
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-01-11 18:23:00 UTC"
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 49/100 indicates moderate opportunity quality",
      "Timing regime: EARLY_BUILD",
      "Historical profile: 1 rallies, 300% best run"
    ],
    "main_risk": "Confidence 40/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "ABDX.L",
      "latest": [
        {
          "title": "Exercise of options and total voting rights",
          "announcement_date": "29th Dec 2025",
          "release_time": "2:35 pm",
          "source": "RNS",
          "content": "29 Dec 2025 14:35\nRNS Number : 0290N\nAbingdon Health PLC\n29 December 2025\nThis announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\nAbingdon Health plc\n(\"Abingdon Health\", the \"Group\" or the \"Company\")\nExercise of options and total voting rights\nYork, U.K. 29 December 2025:\nAbingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and distributor of high quality and effective rapid tests, announces that it has applied for 5,208 new ordinary shares of 0.025 pence each (\"Ordinary Shares\") in the Company to be admitted to trading on AIM on 30 December 2025 following an exercise of share options.\nFollowing the issue of the 5,208 new Ordinary Shares the Company will have a total of 251,077,850 Ordinary Shares in issue. The Company does not hold any shares in Treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. The above information is provided by the Company in accordance with its obligations under the FCA's Disclosure Guidance and Transparency Rules.\nEnquiries:\nAbingdon Health plc\nwww.abingdonhealth.com/investors/\nChris Hand,\u00a0Executive\nChairman\nVia Walbrook PR\nT\nom Hayes, CFO\nZeus (Sole Broker and Nominated Adviser)\nTel:\n+44 (0)20 3829 5000\nAntonio Bossi / Jacob Walker (Corporate Finance)\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or\nabingdon@walbrookpr.com\nPaul McManus\u00a0/\u00a0Alice Woodings\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\nAbout Abingdon Health\nAbingdon Health\u00a0Group\u00a0is a leading med-tech contract service provider offering its services to an international customer base.\nThe Group's\nCDMO\n(Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.\nAbingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring. The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other\nin vitro\ndiagnostic assays from its Doncaster, England facilities.\nFounded in 2008,\u00a0Abingdon Health\u00a0is headquartered in\u00a0York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.\nAbingdon Health's\nbrochure\noutlines the comprehensive support the Group can now provide to its international customers. For more information visit:\nwww.abingdonhealth.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nIOEPKCBNQBDDDBB"
        },
        {
          "title": "Exercise of options and total voting rights",
          "announcement_date": "29th Dec 2025",
          "release_time": "2:35 pm",
          "source": "RNS",
          "content": "29 Dec 2025 14:35\nRNS Number : 0290N\nAbingdon Health PLC\n29 December 2025\nThis announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.\nAbingdon Health plc\n(\"Abingdon Health\", the \"Group\" or the \"Company\")\nExercise of options and total voting rights\nYork, U.K. 29 December 2025:\nAbingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and distributor of high quality and effective rapid tests, announces that it has applied for 5,208 new ordinary shares of 0.025 pence each (\"Ordinary Shares\") in the Company to be admitted to trading on AIM on 30 December 2025 following an exercise of share options.\nFollowing the issue of the 5,208 new Ordinary Shares the Company will have a total of 251,077,850 Ordinary Shares in issue. The Company does not hold any shares in Treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. The above information is provided by the Company in accordance with its obligations under the FCA's Disclosure Guidance and Transparency Rules.\nEnquiries:\nAbingdon Health plc\nwww.abingdonhealth.com/investors/\nChris Hand,\u00a0Executive\nChairman\nVia Walbrook PR\nT\nom Hayes, CFO\nZeus (Sole Broker and Nominated Adviser)\nTel:\n+44 (0)20 3829 5000\nAntonio Bossi / Jacob Walker (Corporate Finance)\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or\nabingdon@walbrookpr.com\nPaul McManus\u00a0/\u00a0Alice Woodings\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\nAbout Abingdon Health\nAbingdon Health\u00a0Group\u00a0is a leading med-tech contract service provider offering its services to an international customer base.\nThe Group's\nCDMO\n(Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.\nAbingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring. The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other\nin vitro\ndiagnostic assays from its Doncaster, England facilities.\nFounded in 2008,\u00a0Abingdon Health\u00a0is headquartered in\u00a0York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.\nAbingdon Health's\nbrochure\noutlines the comprehensive support the Group can now provide to its international customers. For more information visit:\nwww.abingdonhealth.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nIOEPKCBNQBDDDBB"
        },
        {
          "title": "European patent for AppDx\u00ae smartphone reader",
          "announcement_date": "18th Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS-R",
          "content": "18 Dec 2025 07:00\nRNS Number : 0252M\nAbingdon Health PLC\n18 December 2025\nAbingdon Health plc\n(\"Abingdon Health\" or \"the Company\")\nEuropean patent for AppDx\n\u00ae\nlateral flow smartphone reader\nYork, U.K.\u00a018 December 2025:\nAbingdon Health plc (AIM: ABDX),\u00a0a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces the granting of an additional patent for its\nAppDx\n\u00ae\nlateral flow smartphone reader.\nThe new European patent \"Assay Reading Method\" with patent number EP4150565 has been granted and follows the recent granting of a similar patent in USA with patent number US 12,373,946 B2, with other patents already granted in UK.\nAppDx\n\u00ae is a software development kit for reading colorimetric lateral-flow tests organized for Android\u2122 and iOS\u00ae smartphone operating systems.\nAppDx\n\u00ae enables lateral-flow test readout from your pocket, enabled by a smartphone camera. It consists of a software application programming interface accessed as a library which contains algorithms for image processing and deep learning in order to read a lateral-flow test using a smartphone. The algorithms are customized and tuned for each test.\nThe Abingdon Health\nAppDx\n\u00ae\nalgorithm reads the lateral flow device qualitatively (e.g. positive/negative) and semi-quantitively (e.g. negative/high/medium/low).\nDr Chris Hand, Executive Chairman of Abingdon Health plc, commented:\n\"We are pleased to announce the granting of a further patent for our\nAppDx\n\u00ae\nlateral flow smartphone lateral flow reader. This is another tool available to our contract development and manufacturing customers and illustrates the continued innovation in the lateral flow market.\"\nEnquiries:\nAbingdon Health plc\nwww.abingdonhealth.com/investors/\nChris Hand,\u00a0Executive\nChairman\nVia Walbrook PR\nTom Hayes, CFO\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or\nabingdon@walbrookpr.com\nPaul McManus\u00a0/\u00a0Alice Woodings\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\nAbout Abingdon Health\nAbingdon Health\u00a0Group\u00a0is a leading med-tech contract service provider offering its services to an international customer base.\nThe Group's\nCDMO\n(Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.\nAbingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring. The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other\nin vitro\ndiagnostic assays from its Doncaster, England facilities.\nFounded in 2008,\u00a0Abingdon Health\u00a0is headquartered in\u00a0York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.\nAbingdon Health's\nbrochure\noutlines the comprehensive support the Group can now provide to its international customers. For more information visit:\nwww.abingdonhealth.com\n.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAFFSESWEISELE"
        },
        {
          "title": "Result of Annual General Meeting",
          "announcement_date": "10th Dec 2025",
          "release_time": "1:47 pm",
          "source": "RNS",
          "content": "10 Dec 2025 13:47\nRNS Number : 0517L\nAbingdon Health PLC\n10 December 2025\nAbingdon Health plc\n(\"Abingdon Health\", the \"Group\" or the \"Company\")\nResult of Annual General Meeting\nYork, UK 10 December 2025:\nAbingdon Health plc (AIM: ABDX),\u00a0a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed with greater than 99.7% of votes in favour.\nEnquiries:\nAbingdon Health plc\nwww.abingdonhealth.com/investors/\nChris Hand,\u00a0Executive\nChairman\nVia Walbrook PR\nT\nom Hayes, CFO\nZeus (Sole Broker and Nominated Adviser)\nTel:\n+44 (0)20 3829 5000\nAntonio Bossi / Jacob Walker (Corporate Finance)\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or\nabingdon@walbrookpr.com\nPaul McManus\u00a0/\u00a0Alice Woodings\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\nAbout Abingdon Health\nAbingdon Health\u00a0Group\u00a0is a leading med-tech contract service provider offering its services to an international customer base.\nThe Group's\nCDMO\n(Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.\nAbingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring. The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other\nin vitro\ndiagnostic assays from its Doncaster, England facilities.\nFounded in 2008,\u00a0Abingdon Health\u00a0is headquartered in\u00a0York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.\nAbingdon Health's\nbrochure\noutlines the comprehensive support the Group can now provide to its international customers. For more information visit:\nwww.abingdonhealth.com\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGURVURVWUUAAA"
        },
        {
          "title": "Vesting and Award of Options under LTIP",
          "announcement_date": "4th Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "4 Dec 2025 07:00\nRNS Number : 1748K\nAbingdon Health PLC\n04 December 2025\nAbingdon Health plc\n(\"Abingdon Health\", the \"Group\" or the \"Company\")\nVesting and Award of Options under LTIP\nYork, UK 4 December 2025:\nAbingdon Health plc (AIM: ABDX),\u00a0a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces updates, under the terms of the existing Long Term Incentive Plan established in\u00a0December 2022\u00a0(\"LTIP\" or the \"Plan\"). The Plan issues share options (\"Options\") over ordinary shares of\u00a00.025 pence\u00a0each (\"Ordinary\u00a0Shares\")\u00a0to certain directors and senior management, in order to incentivise and encourage retention in a manner that aligns with the interests of the Company's shareholders.\nRegarding the FY23 LTIP, 16% of the LTIPs awarded in December 2022 have now vested against performance criteria for the financial year ended 30 June 2025 (\"FY25\"), based on revenue and EBITDA targets. A total of 512,800 shares with an exercise price of 7 pence have vested as illustrated below, with 2,692,199 LTIP shares from the FY23 scheme lapsing.\nPDMR\nRole\nOptions vested and exercisable under the FY23 LTIP (FY23-FY25 inclusive)\nLapsed LTIP under the FY23 LTIP\nChris Hand\nExecutive Chairman\n68,571\n360,000\nChris Yates\nChief Commercial Officer President,\u00a0Abingdon Health USA\n205,714\n1,080,000\nMark Jones\nChief Operating Officer\n96,000\n504,000\nNina Garrett\nChief Technical Officer\n82,400\n432,600\nCandice Vendettuoli\nDirector of QARA\n45,714\n240,000\nNatalie Thrush\nChief of Staff/Head of HR\n14,400\n75,600\nIn addition, under the terms of the Plan,\u00a0the Company has awarded new nil cost LTIPs totalling 3,361,000 shares which will vest circa October 2028, following publication of audited accounts for the financial year ending 30 June 2028 (\"FY28\"), and subject to achieving performance targets based on revenue and EBITDA for performance in FY28. 50% of these new awards are based on achieving revenue targets and 50% are based on EBITDA targets.\nNew and existing LTIPs are summarised below:\nPDMR\nRole\nExisting LTIPs less those lapsed from FY23\nNew FY26 LTIPs\nTotal less lapsed FY23\nChris Hand\nExecutive Chairman\n1,298,057\n946,000\n2,244,057\nTom Hayes\nChief Financial Officer\n660,000\n660,000\n1,320,000\nChris Yates\nChief Commercial Officer President,\u00a0Abingdon Health USA\n2,002,173\n555,000\n2,557,173\nMark Jones\nChief Operating Officer\n997,376\n300,000\n1,297,376\nNina Garrett\nChief Technical Officer\n839,556\n300,000\n1,139,556\nCandice Vendettuoli\nDirector of QARA\n549,200\n300,000\n849,200\nNatalie Thrush\nChief of Staff/Head of HR\n383,207\n300,000\n683,207\nThe total LTIP share options outstanding, less those which have now lapsed from the FY23 scheme, from FY23, FY24, FY25 and FY26 is 10,090,570. If all these LTIP options were to vest and be exercised this equates to 3.86% of ordinary shares post exercise of options.\nEnquiries:\nAbingdon Health plc\nwww.abingdonhealth.com/investors/\nChris Hand,\u00a0Executive\nChairman\nVia Walbrook PR\nT\nom Hayes, CFO\nZeus (Sole Broker and Nominated Adviser)\nTel:\n+44 (0)20 3829 5000\nAntonio Bossi / Jacob Walker (Corporate Finance)\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or\nabingdon@walbrookpr.com\nPaul McManus\u00a0/\u00a0Alice Woodings\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\nAbout Abingdon Health\nAbingdon Health\u00a0Group\u00a0is a leading med-tech contract service provider offering its services to an international customer base.\nThe Group's\nCDMO\n(Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success.\nAbingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring. The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other\nin vitro\ndiagnostic assays from its Doncaster, England facilities.\nFounded in 2008,\u00a0Abingdon Health\u00a0is headquartered in\u00a0York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.\nAbingdon Health's\nbrochure\noutlines the comprehensive support the Group can now provide to its international customers. For more information visit:\nwww.abingdonhealth.com\n.\n1\nDetails of the person discharging managerial responsibilities/person closely associated\na)\nName:\nChris Hand\n2\nReason for the notification\na)\nPosition/Status:\nExecutive Chairman\nb)\nInitial Notification/Amendment:\nInitial Notification\n3\nDetails of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor\na)\nName:\nAbingdon Health plc\nb)\nLEI:\n213800XFI4WV3FBILO20\n4.\nDetails of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n.\na)\nDescription of the financial instrument:\nIdentification code:\nOrdinary Shares of 0.025 pence each\nGB00BLF79J41\nb)\nNature of the transaction:\nAward of LTIP Options\nc)\nPrice(s) and volume(s):\nPrice(s)\nVolume(s)\nNil\n946,000\nd)\nAggregated volume:\nPrice:\nSee above\ne)\nDate of the Transaction:\n3 December 2025\nf)\nPlace of the Transaction:\nOutside a trading venue\n1\nDetails of the person discharging managerial responsibilities/person closely associated\na)\nName:\nChris Yates\n2\nReason for the notification\na)\nPosition/Status:\nChief Commercial Officer / President, Abingdon Health USA\nb)\nInitial Notification/Amendment:\nInitial Notification\n3\nDetails of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor\na)\nName:\nAbingdon Health plc\nb)\nLEI:\n213800XFI4WV3FBILO20\n4.\nDetails of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n.\na)\nDescription of the financial instrument:\nIdentification code:\nOrdinary Shares of 0.025 pence each\nGB00BLF79J41\nb)\nNature of the transaction:\nAward of LTIP Options\nc)\nPrice(s) and volume(s):\nPrice(s)\nVolume(s)\nNil\n555,000\nd)\nAggregated volume:\nPrice:\nSee above\ne)\nDate of the Transaction:\n3 December 2025\nf)\nPlace of the Transaction:\nOutside a trading venue\n1\nDetails of the person discharging managerial responsibilities/person closely associated\na)\nName:\nTom Hayes\n2\nReason for the notification\na)\nPosition/Status:\nChief Financial Officer\nb)\nInitial Notification/Amendment:\nInitial Notification\n3\nDetails of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor\na)\nName:\nAbingdon Health plc\nb)\nLEI:\n213800XFI4WV3FBILO20\n4.\nDetails of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n.\na)\nDescription of the financial instrument:\nIdentification code:\nOrdinary Shares of 0.025 pence each\nGB00BLF79J41\nb)\nNature of the transaction:\nAward of LTIP Options\nc)\nPrice(s) and volume(s):\nPrice(s)\nVolume(s)\nNil\n660,000\nd)\nAggregated volume:\nPrice:\nSee above\ne)\nDate of the Transaction:\n3 December 2025\nf)\nPlace of the Transaction:\nOutside a trading venue\n1\nDetails of the person discharging managerial responsibilities/person closely associated\na)\nName:\nMark Jones\n2\nReason for the notification\na)\nPosition/Status:\nChief Operating Officer\nb)\nInitial Notification/Amendment:\nInitial Notification\n3\nDetails of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor\na)\nName:\nAbingdon Health plc\nb)\nLEI:\n213800XFI4WV3FBILO20\n4.\nDetails of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n.\na)\nDescription of the financial instrument:\nIdentification code:\nOrdinary Shares of 0.025 pence each\nGB00BLF79J41\nb)\nNature of the transaction:\nAward of LTIP Options\nc)\nPrice(s) and volume(s):\nPrice(s)\nVolume(s)\nNil\n300,000\nd)\nAggregated volume:\nPrice:\nSee above\ne)\nDate of the Transaction:\n3 December 2025\nf)\nPlace of the Transaction:\nOutside a trading venue\n1\nDetails of the person discharging managerial responsibilities/person closely associated\na)\nName:\nNina Garrett\n2\nReason for the notification\na)\nPosition/Status:\nChief Technical Officer\nb)\nInitial Notification/Amendment:\nInitial Notification\n3\nDetails of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor\na)\nName:\nAbingdon Health plc\nb)\nLEI:\n213800XFI4WV3FBILO20\n4.\nDetails of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n.\na)\nDescription of the financial instrument:\nIdentification code:\nOrdinary Shares of 0.025 pence each\nGB00BLF79J41\nb)\nNature of the transaction:\nAward of LTIP Options\nc)\nPrice(s) and volume(s):\nPrice(s)\nVolume(s)\nNil\n300,000\nd)\nAggregated volume:\nPrice:\nSee above\ne)\nDate of the Transaction:\n3 December 2025\nf)\nPlace of the Transaction:\nOutside a trading venue\n1\nDetails of the person discharging managerial responsibilities/person closely associated\na)\nName:\nCandice Vendettuoli\n2\nReason for the notification\na)\nPosition/Status:\nDirector of QARA\nb)\nInitial Notification/Amendment:\nInitial Notification\n3\nDetails of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor\na)\nName:\nAbingdon Health plc\nb)\nLEI:\n213800XFI4WV3FBILO20\n4.\nDetails of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n.\na)\nDescription of the financial instrument:\nIdentification code:\nOrdinary Shares of 0.025 pence each\nGB00BLF79J41\nb)\nNature of the transaction:\nAward of LTIP Options\nc)\nPrice(s) and volume(s):\nPrice(s)\nVolume(s)\nNil\n300,000\nd)\nAggregated volume:\nPrice:\nSee above\ne)\nDate of the Transaction:\n3 December 2025\nf)\nPlace of the Transaction:\nOutside a trading venue\n1\nDetails of the person discharging managerial responsibilities/person closely associated\na)\nName:\nNatalie Thrush\n2\nReason for the notification\na)\nPosition/Status:\nChief of Staff / Head of HR\nb)\nInitial Notification/Amendment:\nInitial Notification\n3\nDetails of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor\na)\nName:\nAbingdon Health plc\nb)\nLEI:\n213800XFI4WV3FBILO20\n4.\nDetails of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n.\na)\nDescription of the financial instrument:\nIdentification code:\nOrdinary Shares of 0.025 pence each\nGB00BLF79J41\nb)\nNature of the transaction:\nAward of LTIP Options\nc)\nPrice(s) and volume(s):\nPrice(s)\nVolume(s)\nNil\n300,000\nd)\nAggregated volume:\nPrice:\nSee above\ne)\nDate of the Transaction:\n3 December 2025\nf)\nPlace of the Transaction:\nOutside a trading venue\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nDSHUPGBWPUPAPPW"
        }
      ],
      "themes": [
        "drilling"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 250,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 866.67,
      "trend_direction": "UP",
      "intelligence_signal": "DEAD_TICKER",
      "activity_level": "DEAD"
    },
    "volatility": {
      "atr_normalized": null,
      "stddev_20d": null
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    }
  },
  "ai_insights": {
    "available": false,
    "reason": "LLM module not loaded or analysis failed"
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +11 (AI_Technical_Score=9.0/20)",
      "Drawdown reversion potential: +18 (Drawdown_Pct=89.3%)",
      "Volume confirmation: +3 (Relative_Volume=1.4)",
      "Pattern reliability: +5 (Rally_Count=1.0)",
      "Upside history: +12 (best_rally_pct=300%)"
    ],
    "technical_score": {
      "points": 11,
      "ai_score": 9.0,
      "reason": "AI Technical Score 9.0/20 translates to 11/25 points"
    },
    "drawdown_score": {
      "points": 18,
      "drawdown_pct": 89.32,
      "reason": "Drawdown of 89.3% gives 18/20 points"
    },
    "volume_score": {
      "points": 3,
      "rel_volume": 1.41,
      "reason": "Relative volume 1.41x gives 3 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 1.0,
      "reason": "1.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 12,
      "best_rally_pct": 300.0,
      "reason": "Best rally of 300% gives 12/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=EARLY_BUILD",
          "current_return_pct=66.7%"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Triangulation not loaded (RNS/social/trends missing)",
        "tag": "HIGH",
        "evidence": [
          "analysis_mode=HISTORICAL_ONLY",
          "confidence_capped_at_65"
        ]
      },
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "EARLY_BUILD",
    "run_multiple": 0.22,
    "current_run_pct": 66.67,
    "avg_historical_run_pct": 300.0
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 49/100 APEX score. Historical data shows 1 rallies averaging 300% upside. Current position: +66.7%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Early accumulation phase. Watch for confirmation before committing size.",
    "confidence_explained": "Confidence 40/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": false,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": false
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}